Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06619990 · ClinicalTrials.gov registry record · Phase 1

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

A Phase 1 study of Ulcerative Colitis (UC), sponsored by Xencor.

Recruiting
Registry status
Phase 1
Development phase
270
Enrollment target
20
Study locations

NCT06619990 is a Phase 1 study of Ulcerative Colitis (UC) that is actively recruiting participants, run by Xencor. The registered enrollment target is 270 participants, below the 749-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06619990, a Phase 1 study of Ulcerative Colitis (UC), is actively recruiting participants, sponsored by Xencor.

RECRUITING
Registry status
Phase 1
Development phase
270 participants
Enrollment target
20
Study locations

Study Summary

Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).

Conditions Studied

Ulcerative Colitis (UC)

Interventions

  • DRUG Placebo
  • BIOLOGICAL XmAb942

Study Locations (20)

Florida

  • Xencor Investigative Site - Bradenton
  • Xencor Investigative Site - Jacksonville
  • Xencor Investigative Site - Kissimmee
  • Xencor Investigative Site - Tampa

Texas

  • Xencor Investigative Site - Denton
  • Xencor Investigative Site - Houston
  • Xencor Investigative Site - Kingwood
  • Xencor Investigative Site - San Antonio

Other

  • Xencor Investigative Site - Sofia
  • Xencor Investigative Site - Zagreb
  • Xencor Investigative Site - Tbilisi

Western Australia

  • Xencor Investigative Site - Joondalup
  • Xencor Investigative Site - Nedlands

Ontario

  • Xencor Investigative Site - London
  • Xencor Investigative Site - Scarborough Village

Arizona

  • Xencor Investigative Site - Scottsdale

North Carolina

  • Xencor Investigative Site - Raleigh

New South Wales

  • Xencor Investigative Site - Wollongong

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2024-10-10
Est. Completion 2029-01
Phase Phase 1

Sponsor

Xencor

27 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06619990

The ClinicalTrials.gov registry entry for NCT06619990 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 749-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (64% lower). The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ulcerative Colitis (UC) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06619990 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Texas, Other.

Frequently Asked Questions

What is clinical trial NCT06619990 about?

NCT06619990 is a clinical study titled "Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis". Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).

What is the current status of trial NCT06619990?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 270 participants. The study started on 2024-10-10. Estimated completion is 2029-01.

What conditions does trial NCT06619990 study?

This clinical trial studies the following conditions: Ulcerative Colitis (UC).

What interventions are being tested in trial NCT06619990?

The interventions under investigation include: Placebo (DRUG), XmAb942 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06619990?

This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06619990 being conducted?

This trial has 20 study locations across Arizona, Florida, North Carolina, Texas, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ulcerative Colitis (UC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ulcerative Colitis (UC)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.